Ketamine-Assisted Group Psychotherapy for Frontline Healthcare Workers with COVID-19-Related Burnout and PTSD: A Case Series of Effectiveness/Safety for 10 Participants

References

• Albott, C. S., K. O. Lim, M. K. Forbes, C. Erbes, S. J. Tye, J. G. Grabowski, P. Thuras, Y. C. T. M. Batres, J. Wels, and P. R. Shiroma. 2018. Efficacy, safety, and durability of repeated ketamine infusions for comorbid posttraumatic stress disorder and treatment-resistant depression. The Journal of Clinical Psychiatry 79 (3). doi:10.4088/JCP.17m11634.
   PubMed Web of Science ®Google Scholar
• APA. 2020. Summary of recommendations of the APA guideline development panel for the treatment of PTSD https://www.apa.org/ptsd-guideline/treatments/recommendations-summary-table.pdf
   Google Scholar
• Barrett, F. S., M. W. Johnson, and R. R. Griffiths. 2015. Validation of the revised mystical experience questionnaire in experimental sessions with psilocybin. Journal of Psychopharmacology (Oxford, England) 29 (11):1182–90. doi:10.1177/0269881115609019.
   PubMed Web of Science ®Google Scholar
• Barsuglia, J., A. K. Davis, R. Palmer, R. Lancelotta, A. -M. Windham-Herman, K. Peterson, M. Polanco, R. Grant, and R. R. Griffiths. 2018. Intensity of mystical experiences occasioned by 5-MeO-DMT and comparison with a prior psilocybin study [Brief Research Report]. Frontiers in Psychology 9:9. doi:10.3389/fpsyg.2018.02459.
   PubMed Web of Science ®Google Scholar
• Dames, S., P. Kryskow, and C. Watler. 2022. A cohort-based case report: The impact of ketamine-assisted therapy embedded in a community of practice framework for healthcare providers with PTSD and depression [Case Report]. Frontiers in Psychiatry 12:12. doi:10.3389/fpsyt.2021.803279.
   Web of Science ®Google Scholar
• Dore, J., B. Turnipseed, S. Dwyer, A. Turnipseed, J. Andries, G. Ascani, C. Monnette, A. Huidekoper, N. Strauss, and P. Wolfson. 2019. Ketamine Assisted Psychotherapy (KAP): Patient demographics, clinical data and outcomes in three large practices administering ketamine with psychotherapy. Journal of Psychoactive Drugs 51 (2):189–98. doi:10.1080/02791072.2019.1587556.
   PubMed Web of Science ®Google Scholar
• Dutheil, F., C. Aubert, B. Pereira, M. Dambrun, F. Moustafa, M. Mermillod, J. S. Baker, M. Trousselard, F. X. Lesage, and V. Navel. 2019. Suicide among physicians and health-care workers: A systematic review and meta-analysis. Plos One 14 (12):e0226361. doi:10.1371/journal.pone.0226361.
   PubMed Web of Science ®Google Scholar
• FDA. 2022. Intravenous Midazolam FDA Label https://s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/002/434/original/Intraveous_Midazolam_FDA_label.pdf?1545435299
   Google Scholar
• Feder, A., S. Costi, S. B. Rutter, A. B. Collins, U. Govindarajulu, M. K. Jha, S. R. Horn, M. Kautz, M. Corniquel, K. A. Collins, et al. 2021. A randomized controlled trial of repeated ketamine administration for chronic posttraumatic stress disorder. The American Journal of Psychiatry 178 (2):193–202. doi:10.1176/appi.ajp.2020.20050596.
   PubMed Web of Science ®Google Scholar
• Feder, A., M. K. Parides, J. W. Murrough, A. M. Perez, J. E. Morgan, S. Saxena, K. Kirkwood, M. Aan Het Rot, K. A. Lapidus, L. B. Wan, et al. 2014. Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: A randomized clinical trial. JAMA Psychiatry 71 (6):681–88. doi:10.1001/jamapsychiatry.2014.62.
   PubMed Web of Science ®Google Scholar
• Feder, A., S. B. Rutter, D. Schiller, and D. S. Charney. 2020. The emergence of ketamine as a novel treatment for posttraumatic stress disorder. Advances in Pharmacology 89:261–86. doi:10.1016/bs.apha.2020.05.004.
   PubMedGoogle Scholar
• Hagerty, S. L., and L. M. Williams. 2022. Moral injury, traumatic stress, and threats to core human needs in health-care workers: The COVID-19 pandemic as a dehumanizing experience. Clinical Psychological Science 21677026211057554. doi:10.1177/21677026211057554.
   Web of Science ®Google Scholar
• Hasler, G. 2020. Toward specific ways to combine ketamine and psychotherapy in treating depression. CNS Spectrums 25 (3):445–47. doi:10.1017/S1092852919001007.
   PubMed Web of Science ®Google Scholar
• Hochschild, A., M. F. Grunebaum, and J. J. Mann. 2021. The rapid anti-suicidal ideation effect of ketamine: A systematic review. Preventive Medicine 152 (Pt 1):106524. doi:10.1016/j.ypmed.2021.106524.
   PubMedGoogle Scholar
• Hoskins, M., J. Pearce, A. Bethell, L. Dankova, C. Barbui, W. A. Tol, M. van Ommeren, J. de Jong, S. Seedat, H. Chen, et al. 2015. Pharmacotherapy for post-traumatic stress disorder: Systematic review and meta-analysis. British Journal of Psychiatry 206 (2):93–100. doi:10.1192/bjp.bp.114.148551.
   PubMed Web of Science ®Google Scholar
• Hough, D. 2019. Esketamine. https://www.fda.gov/media/121379/download
   Google Scholar
• Kim, J., T. Farchione, A. Potter, Q. Chen, and R. Temple. 2019. Esketamine for treatment-resistant depression - First FDA-Approved antidepressant in a new class. The New England Journal of Medicine 381 (1):1–4. doi:10.1056/NEJMp1903305.
   PubMed Web of Science ®Google Scholar
• Krediet, E., T. Bostoen, J. Breeksema, A. van Schagen, T. Passie, and E. Vermetten. 2020. Reviewing the potential of psychedelics for the treatment of PTSD. The International Journal of Neuropsychopharmacology 23 (6):385–400. doi:10.1093/ijnp/pyaa018.
   PubMed Web of Science ®Google Scholar
• Kristensen, T., M. Borritz, E. Villadsen, and K. Christensen. 2005. The Copenhagen burnout inventory: A new tool for the assessment of burnout. Work and Stress 19:192–207. doi:10.1080/02678370500297720.
   Web of Science ®Google Scholar
• Kroenke, K. 2012. Enhancing the clinical utility of depression screening. Canadian Medical Association Journal 184 (3):281–82. doi:10.1503/cmaj.112004.
   PubMed Web of Science ®Google Scholar
• Kroenke, K., R. L. Spitzer, and J. B. Williams. 2001. The PHQ-9: Validity of a brief depression severity measure. Journal of General Internal Medicine 16 (9):606–13. doi:10.1046/j.1525-1497.2001.016009606.x.
   PubMed Web of Science ®Google Scholar
• Liriano, F., C. Hatten, and T. L. Schwartz. 2019. Ketamine as treatment for post-traumatic stress disorder: A review. Drugs Context 8:212305. doi:10.7573/dic.212305.
   PubMedGoogle Scholar
• Maclean, K. A., J. -M.S. Leoutsakos, M. W. Johnson, and R. R. Griffiths. 2012. Factor analysis of the mystical experience questionnaire: A study of experiences occasioned by the hallucinogen psilocybin. Journal for the Scientific Study of Religion 51 (4):721–37. doi:10.1111/j.1468-5906.2012.01685.x.
   PubMed Web of Science ®Google Scholar
• Marvaldi, M., J. Mallet, C. Dubertret, M. R. Moro, and S. B. Guessoum. 2021. Anxiety, depression, trauma-related, and sleep disorders among healthcare workers during the COVID-19 pandemic: A systematic review and meta-analysis. Neuroscience and Biobehavioral Reviews 126:252–64. doi:10.1016/j.neubiorev.2021.03.024.
   PubMed Web of Science ®Google Scholar
• McIntyre, R. S., I. P. Carvalho, L. M. W. Lui, A. Majeed, P. S. Masand, H. Gill, N. B. Rodrigues, O. Lipsitz, A. C. Coles, Y. Lee, et al. 2020. The effect of intravenous, intranasal, and oral ketamine in mood disorders: A meta-analysis. Journal of Affective Disorders 276:576–84. doi:10.1016/j.jad.2020.06.050.
   PubMed Web of Science ®Google Scholar
• McIntyre, J. D. Rosenblat, C. B. Nemeroff, G. Sanacora, J. W. Murrough, M. Berk, E. Brietzke, S. Dodd, P. Gorwood, R. Ho, et al. 2021. Synthesizing the evidence for ketamine and esketamine in treatment-resistant depression: An international expert opinion on the available evidence and implementation. The American Journal of Psychiatry 178 (5):383–99. doi:10.1176/appi.ajp.2020.20081251.
   PubMed Web of Science ®Google Scholar
• Medscape. 2019. Medscape national physician burnout and suicide report 2020.
   Google Scholar
• Medscape. 2021. Death by 1,000 cuts: Medscape national physician burnout and suicide Report 2021.
   Google Scholar
• Mitchell, J. M., M. Bogenschutz, A. Lilienstein, C. Harrison, S. Kleiman, K. Parker-Guilbert, G. M. Ot’alora, W. Garas, C. Paleos, I. Gorman, et al. 2021. MDMA-assisted therapy for severe PTSD: A randomized, double-blind, placebo-controlled phase 3 study. Nature Medicine 27 (6):1025–33. doi:10.1038/s41591-021-01336-3.
   PubMed Web of Science ®Google Scholar
• Moghaddam, B. 2021. Ketamine. MIT Press. https://books.google.com/books?id=QP5gzQEACAAJ.
   Google Scholar
• Newport, D. J., L. L. Carpenter, W. M. McDonald, J. B. Potash, M. Tohen, and C. B. Nemeroff. 2015. Ketamine and other NMDA antagonists: Early clinical trials and possible mechanisms in depression. The American Journal of Psychiatry 172 (10):950–66. doi:10.1176/appi.ajp.2015.15040465.
   PubMed Web of Science ®Google Scholar
• Pereira-Lima, K., D. A. Mata, S. R. Loureiro, J. A. Crippa, L. M. Bolsoni, and S. Sen. 2019 e1916097-e1916097. Association between physician depressive symptoms and medical errors: a systematic review and meta-analysis. JAMA Network Open. 2 (11). doi:10.1001/jamanetworkopen.2019.16097.
   PubMed Web of Science ®Google Scholar
• Phillips, J. L., S. Norris, J. Talbot, T. Hatchard, A. Ortiz, M. Birmingham, O. Owoeye, L. A. Batten, and P. Blier. 2020. Single and repeated ketamine infusions for reduction of suicidal ideation in treatment-resistant depression. Neuropsychopharmacology 45 (4):606–12. doi:10.1038/s41386-019-0570-x.
   PubMed Web of Science ®Google Scholar
• Rodriguez, P., D. W. Holowka, and B. P. Marx. 2012. Assessment of posttraumatic stress disorder-related functional impairment: A review. Journal of Rehabilitation Research and Development 49 (5):649–65. doi:10.1682/jrrd.2011.09.0162.
   PubMed Web of Science ®Google Scholar
• Roseman, L., E. Haijen, K. Idialu-Ikato, M. Kaelen, R. Watts, and R. Carhart-Harris. 2019. Emotional breakthrough and psychedelics: Validation of the emotional breakthrough inventory. Journal of Psychopharmacology 33 (9):1076–87. doi:10.1177/0269881119855974.
   PubMed Web of Science ®Google Scholar
• Rosendahl, J., C. T. Alldredge, G. M. Burlingame, and B. Strauss. 2021. Recent developments in group psychotherapy research. American Journal of Psychotherapy 74 (2):52–59. doi:10.1176/appi.psychotherapy.20200031.
   PubMed Web of Science ®Google Scholar
• Sanacora, G., M. A. Frye, W. McDonald, S. J. Mathew, M. S. Turner, A. F. Schatzberg, P. Summergrad, and C. B. Nemeroff. 2017. A consensus statement on the use of ketamine in the treatment of mood disorders. JAMA Psychiatry 74 (4):399–405. doi:10.1001/jamapsychiatry.2017.0080.
   PubMed Web of Science ®Google Scholar
• Sessa, B. 2017. MDMA and PTSD treatment: “PTSD: From novel pathophysiology to innovative therapeutics”. Neuroscience Letters 649:176–80. doi:10.1016/j.neulet.2016.07.004.
   PubMed Web of Science ®Google Scholar
• Spitzer, R. L., K. Kroenke, J. B. W. Williams, and B. Löwe. 2006. A brief measure for assessing generalized anxiety disorder: The GAD-7. Archives of Internal Medicine 166 (10):1092–97. doi:10.1001/archinte.166.10.1092.
   PubMed Web of Science ®Google Scholar
• Szarmach, J., W. J. Cubała, A. Włodarczyk, and M. S. Wiglusz. 2019. Short-term ketamine administration in treatment-resistant depression: Focus on cardiovascular safety. Psychiatria Danubina 31 (Suppl 3):585–90.
   PubMedGoogle Scholar
• Tawfik, D. S., A. Scheid, J. Profit, T. Shanafelt, M. Trockel, K. C. Adair, J. B. Sexton, and J. P. A. Ioannidis. 2019. Evidence relating health care provider burnout and quality of care. Annals of Internal Medicine 171 (8):555–67. doi:10.7326/M19-1152.
   PubMed Web of Science ®Google Scholar
• Toussaint, A., P. Hüsing, A. Gumz, K. Wingenfeld, M. Härter, E. Schramm, and B. Löwe. 2020. Sensitivity to change and minimal clinically important difference of the 7-item Generalized Anxiety Disorder questionnaire (GAD-7). Journal of Affective Disorders 265:395–401. doi:10.1016/j.jad.2020.01.032.
   PubMed Web of Science ®Google Scholar
• VA. 2022. Using the PTSD Checklist for DSM-5 (PCL-5) https://www.ptsd.va.gov/professional/assessment/documents/using-PCL5.pdf
   Google Scholar
• Walsh, Z., O. M. Mollaahmetoglu, J. Rootman, S. Golsof, J. Keeler, B. Marsh, D. J. Nutt, and C. J. A. Morgan. 2022. Ketamine for the treatment of mental health and substance use disorders: Comprehensive systematic review. BJPsych Open 8 (1):e19. Article e19. doi:10.1192/bjo.2021.1061.
   Web of Science ®Google Scholar
• Yalom, I. D. 1995. The theory and practice of group psychotherapy. 4th. New York, NY: Basic Books.
   Google Scholar
• Zuromski, K. L., B. Ustun, I. Hwang, T. M. Keane, B. P. Marx, M. B. Stein, R. J. Ursano, and R. C. Kessler. 2019. Developing an optimal short-form of the PTSD checklist for DSM-5 (PCL-5). Depression and Anxiety 36 (9):790–800. doi:10.1002/da.22942.
   PubMed Web of Science ®Google Scholar